Technical Analysis for RANI - Rani Therapeutics Holdings, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Evening Star | Bearish | -1.00% | |
| Fell Below 20 DMA | Bearish | -1.00% | |
| Fell Below 50 DMA | Bearish | -1.00% | |
| 180 Bearish Setup | Bearish Swing Setup | -1.00% | |
| Bollinger Band Squeeze | Range Contraction | -1.00% | |
| Gapped Down | Weakness | -1.00% | |
| 20 DMA Support | Bullish | -6.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 10 hours ago |
| Bearish 180 Entry | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
| Down 1% | about 10 hours ago |
| Up 1% | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/28/2023
Rani Therapeutics Holdings, Inc. Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Endocrine System Osteoporosis Peptide Hormones Growth Hormone Glands Glucagon Growth Hormone Deficiency Neuroendocrine Tumors Psoriatic Arthritis Acromegaly Hypoparathyroidism Neuroendocrinology Parathyroid Hormone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 14.75 |
| 52 Week Low | 4.92 |
| Average Volume | 31,874 |
| 200-Day Moving Average | 8.28 |
| 50-Day Moving Average | 6.08 |
| 20-Day Moving Average | 6.31 |
| 10-Day Moving Average | 6.20 |
| Average True Range | 0.37 |
| RSI | 43.82 |
| ADX | 13.66 |
| +DI | 14.63 |
| -DI | 21.36 |
| Chandelier Exit (Long, 3 ATRs) | 5.77 |
| Chandelier Exit (Short, 3 ATRs) | 6.82 |
| Upper Bollinger Bands | 6.76 |
| Lower Bollinger Band | 5.87 |
| Percent B (%b) | 0.09 |
| BandWidth | 14.20 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.06 |
| MACD Histogram | -0.0498 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.28 | ||||
| Resistance 3 (R3) | 6.30 | 6.21 | 6.23 | ||
| Resistance 2 (R2) | 6.21 | 6.13 | 6.20 | 6.21 | |
| Resistance 1 (R1) | 6.08 | 6.07 | 6.04 | 6.06 | 6.19 |
| Pivot Point | 5.99 | 5.99 | 5.97 | 5.98 | 5.99 |
| Support 1 (S1) | 5.86 | 5.91 | 5.82 | 5.84 | 5.71 |
| Support 2 (S2) | 5.77 | 5.85 | 5.76 | 5.69 | |
| Support 3 (S3) | 5.64 | 5.77 | 5.68 | ||
| Support 4 (S4) | 5.62 |
